Brief: Valbiotis Announces Its Roadmap For 2023

Valbiotis SA

10/01/2023 06:48

Jan 10 (Reuters) - Valbiotis SA  ALVAL.PA :
    * VALBIOTIS ANNOUNCES ITS ROADMAP FOR 2023: A PIVOTAL YEAR
IN THE
EXECUTION OF ITS CLINICAL, INDUSTRIAL AND COMMERCIAL STRATEGY
    * A DECISIVE YEAR IN CLINICAL TERMS WITH RESULTS EXPECTED IN
FIRST
HALF OF 2023 FROM INTERNATIONAL PHASE II/III REVERSE-IT STUDY ON
TOTUM•63
    * RAMP-UP OF INDUSTRIAL AND COMMERCIAL OPERATIONS WITH A
VIEW TO
SUPPLYING NESTLÉ HEALTH SCIENCE WITH FIRST COMMERCIAL BATCHES OF
TOTUM•63 AND MARKETING TOTUM•070 (LDL HYPERCHOLESTEROLEMIA) IN
FRANCE IN FIRST HALF OF 2024
    * FOR 2023 EXPECTS INTENSIFICATION OF BUSINESS DEVELOPMENT
ACTIVITIES FOR EXPECTED SIGNATURE OF A LICENSING AND/OR
DISTRIBUTION PARTNERSHIP FOR TOTUM•070 INTERNATIONALLY
    * VALBIOTIS IS GEARING UP FOR LAUNCH OF TOTUM•070 IN FIRST
HALF OF
2024, TO BE FOLLOWED BY TOTUM•448 AND TOTUM•854

Source text for Eikon:  ID:nBw8FJ46Ra 
Further company coverage:  ALVAL.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))